Similar Articles
351 Systemic treatment for unresectable hepatocellular carcinoma
352 Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
353 Predictors of early and late hepatocellular carcinoma recurrence
354 Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin
355 Current status and prospect of treatments for recurrent hepatocellular carcinoma
356 Network meta-analysis of the prognosis of curative treatment strategies for recurrent hepatocellular carcinoma after hepatectomy
357 Stenting as a bridge to surgery in obstructing colon cancer: Long-term recurrence pattern and competing risk of mortality
358 Type 2 diabetes mellitus characteristics affect hepatocellular carcinoma development in chronic hepatitis B patients with cirrhosis
359 Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
360 Saccharomyces cerevisiae prevents postoperative recurrence of Crohn's disease modeled by ileocecal resection in HLA-B27 transgenic rats
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA